Dr James E Crowe

All Stories

1. 
   Ultrapotent human antibodies lock E protein dimers central region of diverse DENV3 morphological variants

   Article • Nature Communications, October 2025, Springer Science + Business Media

   Dr James E Crowe

2. 
   Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine

   Article • Journal of Clinical Investigation, July 2025, American Society for Clinical Investigation

   Dr James E Crowe

3. 
   Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses

   Article • Nature Communications, July 2025, Springer Science + Business Media

   Dr James E Crowe

4. 
   Pan-H7 influenza human antibody virus neutralization depends on avidity and steric hindrance

   Article • JCI Insight, June 2025, American Society for Clinical Investigation

   Dr Robert H Carnahan, Dr James E Crowe

5. 
   Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen

   Article • September 2024, Cold Spring Harbor Laboratory Press

   Dr James E Crowe

6. 
   Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques

   Article • August 2024, Cold Spring Harbor Laboratory Press

   Dr Robert H Carnahan, Dr James E Crowe

7. 
   Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis

   Article • JCI Insight, August 2024, American Society for Clinical Investigation

   Dr James E Crowe

8. 
   Functional and antigenic landscape of the Nipah virus receptor binding protein

   Article • April 2024, Cold Spring Harbor Laboratory Press

   Dr James E Crowe

9. 
   Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses.

   Article • March 2024, Springer Science + Business Media

   Dr James E Crowe

10. 
    Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity

    Article • The Journal of Immunology, March 2024, The American Association of Immunologists

    Dr Robert H Carnahan, Dr James E Crowe

11. 
    Andes virus mRNA vaccines: comparison of unmodified and modified mRNA platforms

    Article • August 2023, Springer Science + Business Media

    Dr James E Crowe

12. 
    A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model

    Article • Nature Communications, July 2023, Springer Science + Business Media

    Dr James E Crowe

13. 
    Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody

    Article • Nature Microbiology, June 2023, Springer Science + Business Media

    Dr James E Crowe

14. 
    A chikungunya virus–like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans

    Article • Science Translational Medicine, May 2023, American Association for the Advancement of Science

    Dr James E Crowe

15. 
    Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system

    Article • April 2023, Springer Science + Business Media

    Dr James E Crowe

16. 
    Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies

    Article • Proceedings of the National Academy of Sciences, March 2023, Proceedings of the National Academy of Sciences

    Dr James E Crowe

17. 
    Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods

    Article • PLoS Computational Biology, December 2022, PLOS

    Dr James E Crowe

18. 
    Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency

    Article • Journal of Clinical Investigation, August 2022, American Society for Clinical Investigation

    Dr James E Crowe

19. 
    Human Monoclonal Antibodies to Escherichia coli Outer Membrane Protein A Porin Domain Cause Aggregation but Do Not Alter In Vivo Bacterial Burdens in a Murine Sepsis Model

    Article • Infection and Immunity, June 2022, ASM Journals

    Dr James E Crowe

20. 
    Computational epitope mapping of class I fusion proteins using Bayes classification

    Article • May 2022, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

21. 
    Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region

    Article • PLoS Pathogens, May 2022, PLOS

    Dr James E Crowe

22. 
    The human antibody sequence space and structural design of the V, J regions, and CDRH3 with Rosetta

    Article • mAbs, May 2022, Taylor & Francis

    Dr James E Crowe

23. 
    Atomic structure of the predominant GII.4 human norovirus capsid reveals novel stability and plasticity

    Article • Nature Communications, March 2022, Springer Science + Business Media

    Dr James E Crowe

24. 
    Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus

    Article • March 2022, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

25. 
    Bispecific antiviral neutralizing antibodies are twice as nice

    Article • Nature Immunology, February 2022, Springer Science + Business Media

    Dr James E Crowe

26. 
    An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

    Article • Nature Medicine, January 2022, Springer Science + Business Media

    Dr James E Crowe

27. 
    B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection

    Article • PLoS Pathogens, January 2022, PLOS

    Dr James E Crowe, Dr Stuart C. Ray

28. 
    An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

    Article • December 2021, Springer Science + Business Media

    Dr James E Crowe

29. 
    An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

    Article • December 2021, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

30. 
    Neutralization Fingerprinting Technology for Characterizing Polyclonal Antibody Responses to Dengue Vaccines

    Article • December 2021, Cold Spring Harbor Laboratory Press

    Dr Robert H Carnahan, Dr James E Crowe

31. 
    Human Monoclonal Antibodies against NS1 Protein Protect against Lethal West Nile Virus Infection

    Article • mBio, October 2021, ASM Journals

    Dr James E Crowe

32. 
    Author Correction: Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses

    Article • Nature Communications, October 2021, Springer Science + Business Media

    Dr James E Crowe

33. 
    Human antibody recognition of H7N9 influenza virus hemagglutinin following natural infection

    Article • JCI Insight, August 2021, American Society for Clinical Investigation

    Dr Robert H Carnahan, Dr James E Crowe

34. 
    Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses

    Article • Nature Communications, July 2021, Springer Science + Business Media

    Dr James E Crowe

35. 
    Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects

    Article • Science Translational Medicine, July 2021, American Association for the Advancement of Science

    Dr James E Crowe

36. 
    RosettaCM for antibodies with very long HCDR3s and low template availability

    Article • Proteins Structure Function and Bioinformatics, July 2021, Wiley

    Dr James E Crowe

37. 
    Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

38. 
    Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition

    Article • Proceedings of the National Academy of Sciences, March 2021, Proceedings of the National Academy of Sciences

    Dr James E Crowe, Dr Alexander N Freiberg

39. 
    Antibody affinity versus dengue morphology influences neutralization

    Article • PLoS Pathogens, February 2021, PLOS

    Dr James E Crowe

40. 
    Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

    Article • January 2021, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

41. 
    Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

    Article • January 2021, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

42. 
    Computationally Designed Cyclic Peptides Derived from an Antibody Loop Increase Breadth of Binding for Influenza Variants

    Article • Structure, October 2020, Elsevier

    Dr James E Crowe

43. 
    Humoral Immunity to Hantavirus Infection

    Article • mSphere, August 2020, ASM Journals

    Dr James E Crowe

44. 
    A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice

    Article • PLoS Pathogens, August 2020, PLOS

    Dr James E Crowe

45. 
    Anti–influenza H7 human antibody targets antigenic site in hemagglutinin head domain interface

    Article • Journal of Clinical Investigation, August 2020, American Society for Clinical Investigation

    Dr James E Crowe

46. 
    PyIR: a scalable wrapper for processing billions of immunoglobulin and T cell receptor sequences using IgBLAST

    Article • BMC Bioinformatics, July 2020, Springer Science + Business Media

    Dr James E Crowe

47. 
    Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis

    Article • PLOS One, July 2020, PLOS

    Dr James E Crowe

48. 
    Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease

    Article • PLoS Pathogens, May 2020, PLOS

    Dr James E Crowe

49. 
    Peptide arrays incubated with three collections of human sera from patients infected with mosquito-borne viruses

    Article • F1000Research, February 2020, Faculty of 1000, Ltd.

    Dr James E Crowe

50. 
    Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses

    Article • F1000Research, February 2020, Faculty of 1000, Ltd.

    Dr James E Crowe

51. 
    Multi-state design of flexible proteins predicts sequences optimal for conformational change

    Article • PLoS Computational Biology, February 2020, PLOS

    Dr James E Crowe

52. 
    Broad dengue neutralization in mosquitoes expressing an engineered antibody

    Article • PLoS Pathogens, January 2020, PLOS

    Dr James E Crowe

53. 
    Human-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoires

    Article • mAbs, January 2020, Taylor & Francis

    Dr James E Crowe

54. 
    Immune repertoire fingerprinting by principal component analysis reveals shared features in subject groups with common exposures

    Article • BMC Bioinformatics, December 2019, Springer Science + Business Media

    Dr James E Crowe

55. 
    Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice

    Article • Cell Host & Microbe, December 2019, Elsevier

    Dr James E Crowe

56. 
    Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies

    Article • Cell Host & Microbe, December 2019, Elsevier

    Dr James E Crowe

57. 
    Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge

    Article • Journal of Experimental Medicine, November 2019, Rockefeller University Press

    Dr James E Crowe

58. 
    Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses

    Article • F1000Research, November 2019, Faculty of 1000, Ltd.

    Dr James E Crowe, Ivette Lorenzana

59. 
    Human VH1-69 Gene-Encoded Human Monoclonal Antibodies against Staphylococcus aureus IsdB Use at Least Three Distinct Modes of Binding To Inhibit Bacterial Growth and Pathogenesis

    Article • mBio, October 2019, ASM Journals

    Dr James E Crowe

60. 
    Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody

    Article • npj Vaccines, October 2019, Springer Science + Business Media

    Dr James E Crowe

61. 
    Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells

    Article • ACS Nano, October 2019, American Chemical Society (ACS)

    Dr James E Crowe

62. 
    Ehrlichia chaffeensis Outer Membrane Protein 1-Specific Human Antibody-Mediated Immunity Is Defined by Intracellular TRIM21-Dependent Innate Immune Activation and Extracellular Neutralization

    Article • Infection and Immunity, September 2019, ASM Journals

    Dr James E Crowe

63. 
    Multi-State Design of Flexible Proteins Predicts Sequences Optimal for Conformational Change

    Article • August 2019, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

64. 
    Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance

    Article • Journal of Clinical Investigation, August 2019, American Society for Clinical Investigation

    Dr James E Crowe, Dr Stuart C. Ray

65. 
    Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes

    Article • Vaccine, July 2019, Elsevier

    Dr James E Crowe

66. 
    New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications

    Article • Biology of Blood and Marrow Transplantation, June 2019, Elsevier

    Dr James E Crowe

67. 
    A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

    Article • Science Immunology, May 2019, American Association for the Advancement of Science

    Dr James E Crowe

68. 
    Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2

    Article • Journal of Virology, May 2019, ASM Journals

    Dr James E Crowe

69. 
    A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface

    Article • Cell, May 2019, Elsevier

    Dr James E Crowe

70. 
    Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk

    Article • Nature Communications, April 2019, Springer Science + Business Media

    Dr James E Crowe

71. 
    Antibody Determinants of Influenza Immunity

    Article • The Journal of Infectious Diseases, April 2019, Oxford University Press (OUP)

    Dr James E Crowe

72. 
    Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains

    Article • Frontiers in Immunology, March 2019, Frontiers

    Dr James E Crowe

73. 
    High frequency of shared clonotypes in human B cell receptor repertoires

    Article • Nature, February 2019, Springer Science + Business Media

    Dr James E Crowe

74. 
    Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection

    Article • Journal of Virology, February 2019, ASM Journals

    Dr James E Crowe

75. 
    Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains

    Article • PLoS Biology, February 2019, PLOS

    Dr James E Crowe

76. 
    Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice

    Article • Cell Reports, February 2019, Elsevier

    Dr James E Crowe

77. 
    Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody

    Article • Structure, February 2019, Elsevier

    Dr James E Crowe

78. 
    Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses

    Article • Proceedings of the National Academy of Sciences, January 2019, Proceedings of the National Academy of Sciences

    Dr James E Crowe

79. 
    Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope

    Article • Proceedings of the National Academy of Sciences, January 2019, Proceedings of the National Academy of Sciences

    Dr James E Crowe

80. 
    Influenza Virus–Specific Human Antibody Repertoire Studies

    Article • The Journal of Immunology, January 2019, The American Association of Immunologists

    Dr James E Crowe

81. 
    Regulating patterns of binding by changes in the heavy/light chain interface of HIV antibodies

    Article • Molecular Systems Design & Engineering, January 2019, Royal Society of Chemistry

    Dr James E Crowe

82. 
    Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth

    Article • PLOS One, December 2018, PLOS

    Dr James E Crowe, Dr Nancy L Haigwood

83. 
    Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine

    Article • Journal of Virology, December 2018, ASM Journals

    Dr James E Crowe

84. 
    Current Understanding of Humoral Immunity to Enterovirus D68

    Article • Journal of the Pediatric Infectious Diseases Society, December 2018, Oxford University Press (OUP)

    Dr James E Crowe

85. 
    Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses

    Article • Gastroenterology, December 2018, Elsevier

    Dr James E Crowe

86. 
    Human mAbs to Staphylococcus aureus IsdA Provide Protection Through Both Heme-Blocking and Fc-Mediated Mechanisms

    Article • The Journal of Infectious Diseases, November 2018, Oxford University Press (OUP)

    Dr James E Crowe

87. 
    Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein

    Article • Nature Microbiology, November 2018, Springer Science + Business Media

    Dr James E Crowe

88. 
    A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions

    Article • Nature Microbiology, November 2018, Springer Science + Business Media

    Dr James E Crowe

89. 
    Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection

    Article • Cell Host & Microbe, November 2018, Elsevier

    Dr Stuart C. Ray, Dr James E Crowe

90. 
    HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design

    Article • Cell Host & Microbe, November 2018, Elsevier

    Dr James E Crowe

91. 
    In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model

    Article • Cell Reports, November 2018, Elsevier

    Dr James E Crowe

92. 
    Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine

    Article • Journal of Virology, September 2018, ASM Journals

    Dr James E Crowe

93. 
    Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap

    Article • PLoS Pathogens, August 2018, PLOS

    Dr James E Crowe

94. 
    Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors

    Article • The Journal of Infectious Diseases, August 2018, Oxford University Press (OUP)

    Dr James E Crowe

95. 
    Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors

    Article • Cell Reports, August 2018, Elsevier

    Palaniappan Ramanathan, Dr James E Crowe

96. 
    Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors

    Article • Cell Reports, August 2018, Elsevier

    Palaniappan Ramanathan, Dr James E Crowe

97. 
    A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

    Article • Cell Host & Microbe, August 2018, Elsevier

    Dr James E Crowe

98. 
    Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

    Article • Cell, August 2018, Elsevier

    Dr James E Crowe

99. 
    A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA

    Article • Nature Communications, July 2018, Springer Science + Business Media

    Dr James E Crowe

100. 
     Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates

     Article • The Journal of Infectious Diseases, July 2018, Oxford University Press (OUP)

     Dr James E Crowe

101. 
     Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein

     Article • Immunity, July 2018, Elsevier

     Dr Robert H Carnahan, Dr James E Crowe

102. 
     Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection

     Article • Cell Host & Microbe, June 2018, Elsevier

     Dr James E Crowe

103. 
     Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region

     Article • Nature Microbiology, May 2018, Springer Science + Business Media

     Palaniappan Ramanathan, Dr James E Crowe

104. 
     Mxra8 is a receptor for multiple arthritogenic alphaviruses

     Article • Nature, May 2018, Springer Science + Business Media

     Dr James E Crowe

105. 
     Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus

     Article • mBio, February 2018, ASM Journals

     Dr James E Crowe

106. 
     Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins

     Article • PLoS Pathogens, February 2018, PLOS

     Dr James E Crowe

107. 
     Integrating linear optimization with structural modeling to increase HIV neutralization breadth

     Article • PLoS Computational Biology, February 2018, PLOS

     Dr James E Crowe

108. 
     OUP accepted manuscript

     Article • The Journal of Infectious Diseases, January 2018, Oxford University Press (OUP)

     Dr James E Crowe

109. 
     The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding

     Article • Cell Host & Microbe, January 2018, Elsevier

     Dr James E Crowe

110. 
     Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms

     Article • Proceedings of the National Academy of Sciences, December 2017, Proceedings of the National Academy of Sciences

     Dr James E Crowe, Dr Stuart C. Ray

111. 
     Role of Non-local Interactions between CDR Loops in Binding Affinity of MR78 Antibody to Marburg Virus Glycoprotein

     Article • Structure, December 2017, Elsevier

     Dr James E Crowe

112. 
     Structure–function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8

     Article • Journal of Biological Chemistry, November 2017, American Society for Biochemistry & Molecular Biology (ASBMB)

     Dr James E Crowe

113. 
     Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans

     Article • Journal of Virology, October 2017, ASM Journals

     Dr James E Crowe

114. 
     Epitope and Paratope Mapping Reveals Temperature-Dependent Alterations in the Dengue-Antibody Interface

     Article • Structure, September 2017, Elsevier

     Dr James E Crowe

115. 
     Immune correlates of protection for dengue: State of the art and research agenda

     Article • Vaccine, August 2017, Elsevier

     Dr James E Crowe

116. 
     Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design

     Article • Cell Host & Microbe, August 2017, Elsevier

     Dr James E Crowe

117. 
     Is It Possible to Develop a “Universal” Influenza Virus Vaccine?

     Article • Cold Spring Harbor Perspectives in Biology, June 2017, Cold Spring Harbor Laboratory Press

     Dr James E Crowe

118. 
     Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques

     Article • PLoS Neglected Tropical Diseases, June 2017, PLOS

     Dr James E Crowe

119. 
     Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance

     Article • JCI Insight, May 2017, American Society for Clinical Investigation

     Dr Stuart C. Ray, Dr James E Crowe

120. 
     Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody

     Article • Science Translational Medicine, April 2017, American Association for the Advancement of Science

     Dr James E Crowe

121. 
     Treating Flu with Skin of Frog

     Article • Immunity, April 2017, Elsevier

     Dr James E Crowe

122. 
     A human antibody against Zika virus crosslinks the E protein to prevent infection

     Article • Nature Communications, March 2017, Nature

     Dr James E Crowe

123. 
     Monoclonal Antibodies Against the Staphylococcus aureus Bicomponent Leukotoxin AB Isolated Following Invasive Human Infection Reveal Diverse Binding and Modes of Action

     Article • The Journal of Infectious Diseases, February 2017, Oxford University Press (OUP)

     Isaac Thomsen, Dr James E Crowe

124. 
     Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis

     Article • Science Translational Medicine, February 2017, American Association for the Advancement of Science

     Dr James E Crowe

125. 
     A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein

     Article • Nature Microbiology, January 2017, Nature

     Dr James E Crowe

126. 
     Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus

     Article • Nature Microbiology, January 2017, Nature

     Dr James E Crowe

127. 
     Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination

     Article • Journal of Virology, December 2016, ASM Journals

     Dr James E Crowe

128. 
     Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice

     Article • Nature, November 2016, Nature

     Dr James E Crowe

129. 
     Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein

     Article • Proceedings of the National Academy of Sciences, October 2016, Proceedings of the National Academy of Sciences

     Dr James E Crowe

130. 
     Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

     Article • Cell, October 2016, Elsevier

     Dr James E Crowe

131. 
     Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody

     Article • Proceedings of the National Academy of Sciences, September 2016, Proceedings of the National Academy of Sciences

     Dr James E Crowe

132. 
     A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses

     Article • Science, September 2016, American Association for the Advancement of Science

     Dr James E Crowe

133. 
     Teaching a Clone to Walk, One Step at a Time

     Article • Cell, September 2016, Elsevier

     Dr James E Crowe

134. 
     Phenome-Wide Association Study to Explore Relationships between Immune System Related Genetic Loci and Complex Traits and Diseases

     Article • PLOS One, August 2016, PLOS

     Dr James E Crowe

135. 
     Structures of Ebola virus GP and sGP in complex with therapeutic antibodies

     Article • Nature Microbiology, August 2016, Springer Science + Business Media

     Dr James E Crowe

136. 
     Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence

     Article • Cell Reports, August 2016, Elsevier

     Dr James E Crowe

137. 
     Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein

     Article • PLOS One, July 2016, PLOS

     Dr James E Crowe

138. 
     Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6

     Article • The Journal of Immunology, July 2016, The American Association of Immunologists

     Dr James E Crowe

139. 
     Recognition of influenza H3N2 variant virus by human neutralizing antibodies

     Article • JCI Insight, July 2016, American Society for Clinical Investigation

     Dr James E Crowe

140. 
     Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding

     Article • PLoS Pathogens, June 2016, PLOS

     Dr James E Crowe

141. 
     Characterization of dengue virus 2 growth in megakaryocyte–erythrocyte progenitor cells

     Article • Virology, June 2016, Elsevier

     Dr James E Crowe

142. 
     Deep sequencing and human antibody repertoire analysis

     Article • Current Opinion in Immunology, June 2016, Elsevier

     Dr James E Crowe

143. 
     A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV

     Article • PLOS One, May 2016, PLOS

     Dr James E Crowe

144. 
     Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1

     Article • mSphere, May 2016, ASM Journals

     Terence Dermody, Dr James E Crowe

145. 
     Improving Loop Modeling of the Antibody Complementarity-Determining Region 3 Using Knowledge-Based Restraints

     Article • PLOS One, May 2016, PLOS

     Dr James E Crowe

146. 
     Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization

     Article • Proceedings of the National Academy of Sciences, April 2016, Proceedings of the National Academy of Sciences

     Dr James E Crowe

147. 
     Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1

     Article • Journal of Virology, March 2016, ASM Journals

     Dr James E Crowe

148. 
     H7N9 influenza virus neutralizing antibodies that possess few somatic mutations

     Article • Journal of Clinical Investigation, March 2016, American Society for Clinical Investigation

     Dr James E Crowe, Dr Randy A Albrecht

149. 
     Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies

     Article • mBio, February 2016, ASM Journals

     Dr James E Crowe

150. 
     Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations

     Article • Molecular Immunology, February 2016, Elsevier

     Dr James E Crowe

151. 
     Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates

     Article • Vaccine, February 2016, Elsevier

     Dr James E Crowe

152. 
     Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies

     Article • Journal of Virology, January 2016, ASM Journals

     Dr James E Crowe

153. 
     Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation

     Article • Haematologica, January 2016, Ferrata Storti Foundation (Haematologica)

     Dr James E Crowe

154. 
     Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection

     Article • Cell, January 2016, Elsevier

     Dr James E Crowe

155. 
     Development of Human Monoclonal Antibodies Against Respiratory Syncytial Virus Using a High Efficiency Human Hybridoma Technique

     Article • January 2016, Springer Science + Business Media

     Dr James E Crowe

156. 
     Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress

     Article • Cell, November 2015, Elsevier

     Dr James E Crowe

157. 
     Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site

     Article • Journal of Virology, October 2015, ASM Journals

     Dr James E Crowe

158. 
     Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity

     Article • Proceedings of the National Academy of Sciences, October 2015, Proceedings of the National Academy of Sciences

     Dr James E Crowe

159. 
     A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies

     Article • mBio, October 2015, ASM Journals

     Dr James E Crowe

160. 
     Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus

     Article • Cell Host & Microbe, September 2015, Elsevier

     Dr James E Crowe

161. 
     Deciphering the human immunome

     Article • Expert Review of Vaccines, August 2015, Informa Healthcare

     Dr James E Crowe

162. 
     Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model

     Article • PLOS One, August 2015, PLOS

     Dr James E Crowe

163. 
     Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein

     Article • PLOS One, July 2015, PLOS

     Dr James E Crowe

164. 
     Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites

     Article • Proceedings of the National Academy of Sciences, July 2015, Proceedings of the National Academy of Sciences

     Dr James E Crowe

165. 
     Design of Protein Multi-specificity Using an Independent Sequence Search Reduces the Barrier to Low Energy Sequences

     Article • PLoS Computational Biology, July 2015, PLOS

     Dr James E Crowe

166. 
     Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers

     Article • Science, July 2015, American Association for the Advancement of Science

     Dr James E Crowe

167. 
     Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus

     Article • Cell Host & Microbe, July 2015, Elsevier

     Dr James E Crowe

168. 
     Spleen Tyrosine Kinase (Syk) Mediates IL-1β Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection

     Article • Journal of Biological Chemistry, June 2015, American Society for Biochemistry & Molecular Biology (ASBMB)

     Dr James E Crowe

169. 
     Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth

     Article • Journal of Clinical Investigation, May 2015, American Society for Clinical Investigation

     Dr James E Crowe, Dr Jean-Philippe Julien

170. 
     Retraction for Messer et al., Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

     Article • Proceedings of the National Academy of Sciences, May 2015, Proceedings of the National Academy of Sciences

     Dr James E Crowe

171. 
     Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics

     Article • The Journal of Infectious Diseases, February 2015, Oxford University Press (OUP)

     Dr James E Crowe

172. 
     A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins

     Article • Nature Communications, February 2015, Springer Science + Business Media

     Dr James E Crowe

173. 
     Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus

     Article • Cell, February 2015, Elsevier

     Dr James E Crowe

174. 
     Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody

     Article • Cell, February 2015, Elsevier

     Dr James E Crowe

175. 
     Influenza Viruses with Receptor-Binding N1 Neuraminidases Occur Sporadically in Several Lineages and Show No Attenuation in Cell Culture or Mice

     Article • Journal of Virology, January 2015, ASM Journals

     Dr James E Crowe

176. 
     Antibodies for Infectious Diseases

     Article • January 2015, ASM Journals

     Dr James E Crowe

177. 
     Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies

     Article • January 2015, ASM Journals

     Dr James E Crowe

178. 
     Committing the Oldest Sins in the Newest Kind of Ways—Antibodies Targeting the Influenza Virus Type A Hemagglutinin Globular Head

     Article • January 2015, ASM Journals

     Dr James E Crowe

179. 
     Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis

     Article • Journal of Virology, October 2014, ASM Journals

     Dr James E Crowe

180. 
     Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

     Article • PLoS Pathogens, October 2014, PLOS

     Dr James E Crowe

181. 
     Isolation of Dengue Virus-Specific Memory B Cells with Live Virus Antigen from Human Subjects following Natural Infection Reveals the Presence of Diverse Novel Functional Groups of Antibody Clones

     Article • Journal of Virology, August 2014, ASM Journals

     Dr James E Crowe

182. 
     Intracellular neutralization of a virus using a cell-penetrating molecular transporter

     Article • Nanomedicine, August 2014, Future Medicine

     Dr James E Crowe

183. 
     Tissue-Specific Expressed Antibody Variable Gene Repertoires

     Article • PLOS One, June 2014, PLOS

     Dr James E Crowe

184. 
     STAT4 Deficiency Fails To Induce Lung Th2 or Th17 Immunity following Primary or Secondary Respiratory Syncytial Virus (RSV) Challenge but Enhances the Lung RSV-Specific CD8+ T Cell Immune Response to Secondary Challenge

     Article • Journal of Virology, June 2014, ASM Journals

     Dr James E Crowe

185. 
     Correction for Messer et al., Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

     Article • Proceedings of the National Academy of Sciences, April 2014, Proceedings of the National Academy of Sciences

     Dr James E Crowe

186. 
     Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

     Article • Virology, April 2014, Elsevier

     Dr James E Crowe

187. 
     Antibody Engineering and Therapeutics

     Article • mAbs, March 2014, Taylor & Francis

     Dr James E Crowe

188. 
     Proof of principle for epitope-focused vaccine design

     Article • Nature, February 2014, Nature

     Dr James E Crowe

189. 
     Combining Single RNA Sensitive Probes with Subdiffraction-Limited and Live-Cell Imaging Enables the Characterization of Virus Dynamics in Cells

     Article • ACS Nano, January 2014, American Chemical Society (ACS)

     Dr James E Crowe

190. 
     Diagnostic errors in interpretation of pediatric musculoskeletal radiographs at common injury sites

     Article • Pediatric Radiology, January 2014, Springer Science + Business Media

     Dr James E Crowe

191. 
     Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

     Article • Proceedings of the National Academy of Sciences, January 2014, Proceedings of the National Academy of Sciences

     Dr James E Crowe

192. 
     A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface

     Article • EMBO Molecular Medicine, January 2014, EMBO

     Dr James E Crowe

193. 
     Paramyxoviruses: Respiratory Syncytial Virus and Human Metapneumovirus

     Article • January 2014, Springer Science + Business Media

     Dr James E Crowe

194. 
     The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein

     Article • mBio, November 2013, ASM Journals

     Dr James E Crowe

195. 
     Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses

     Article • Journal of Clinical Investigation, November 2013, American Society for Clinical Investigation

     Dr James E Crowe

196. 
     Differential Accessibility of a Rotavirus VP6 Epitope in Trimers Comprising Type I, II, or III Channels as Revealed by Binding of a Human Rotavirus VP6-Specific Antibody

     Article • Journal of Virology, October 2013, ASM Journals

     Dr James E Crowe

197. 
     Impact of new sequencing technologies on studies of the human B cell repertoire

     Article • Current Opinion in Immunology, October 2013, Elsevier

     Dr James E Crowe

198. 
     Intermittent Testicular Torsion in the Pediatric Patient: Sonographic Indicators of a Difficult Diagnosis

     Article • American Journal of Roentgenology, October 2013, American Roentgen Ray Society

     Dr James E Crowe

199. 
     Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site

     Article • Journal of Virology, September 2013, ASM Journals

     Dr James E Crowe

200. 
     Exposure to Family Members: Infections and Recent Live Vaccinations

     Article • September 2013, Wiley

     Dr James E Crowe

201. 
     Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses

     Article • Journal of Clinical Investigation, September 2013, American Society for Clinical Investigation

     Dr James E Crowe

202. 
     Universal Flu Vaccines: Primum non nocere

     Article • Science Translational Medicine, August 2013, American Association for the Advancement of Science

     Dr James E Crowe

203. 
     Gold nanorod vaccine for respiratory syncytial virus

     Article • Nanotechnology, June 2013, Institute of Physics Publishing

     Dr James E Crowe

204. 
     Anti Rotavirus Antibody

     Article • May 2013, Protein Data Bank, Rutgers University

     Dr James E Crowe

205. 
     Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore

     Article • PLOS One, May 2013, PLOS

     Dr James E Crowe

206. 
     Crowdsourcing Immunity

     Article • Science, May 2013, American Association for the Advancement of Science

     Dr James E Crowe

207. 
     Human Germline Antibody Gene Segments Encode Polyspecific Antibodies

     Article • PLoS Computational Biology, April 2013, PLOS

     Dr James E Crowe

208. 
     E107 Complexity of human naïve B cell repertoires

     Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2013, Wolters Kluwer Health

     Dr James E Crowe

209. 
     Discovering naturally processed antigenic determinants that confer protective T cell immunity

     Article • Journal of Clinical Investigation, April 2013, American Society for Clinical Investigation

     Dr James E Crowe

210. 
     Human Monoclonal Antibodies Derived From Memory B Cells Following Live Attenuated Dengue Virus Vaccination or Natural Infection Exhibit Similar Characteristics

     Article • The Journal of Infectious Diseases, March 2013, Oxford University Press (OUP)

     Dr James E Crowe

211. 
     Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model

     Article • mAbs, March 2013, Taylor & Francis

     Dr James E Crowe

212. 
     Reversion of Somatic Mutations of the Respiratory Syncytial Virus-Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency

     Article • The Journal of Immunology, March 2013, The American Association of Immunologists

     Dr James E Crowe

213. 
     A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin

     Article • Nature Structural & Molecular Biology, February 2013, Springer Science + Business Media

     Dr James E Crowe

214. 
     Secondary mechanisms of diversification in the human antibody repertoire

     Article • Frontiers in Immunology, January 2013, Frontiers

     Dr James E Crowe

215. 
     Molecular mechanisms driving respiratory syncytial virus assembly

     Article • Future Microbiology, January 2013, Future Medicine

     Dr James E Crowe

216. 
     Respiratory Syncytial Virus Regulates Human MicroRNAs by Using Mechanisms Involving Beta Interferon and NF-κB

     Article • mBio, December 2012, ASM Journals

     Dr James E Crowe

217. 
     Influenza Human Monoclonal Antibody 1F1 Interacts with Three Major Antigenic Sites and Residues Mediating Human Receptor Specificity in H1N1 Viruses

     Article • PLoS Pathogens, December 2012, PLOS

     Dr James E Crowe

218. 
     A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis

     Article • Virology, December 2012, Elsevier

     Dr James E Crowe

219. 
     Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival

     Article • Experimental Hematology, December 2012, Elsevier

     Dr James E Crowe

220. 
     Unusual Features of Vaccinia Virus Extracellular Virion Form Neutralization Resistance Revealed in Human Antibody Responses to the Smallpox Vaccine

     Article • Journal of Virology, November 2012, ASM Journals

     Dr James E Crowe

221. 
     Erratum: Corrigendum: Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors

     Article • Nature, September 2012, Springer Science + Business Media

     Dr James E Crowe

222. 
     A Chemically Programmed Antibody Is a Long-Lasting and Potent Inhibitor of Influenza Neuraminidase

     Article • ChemBioChem, September 2012, Wiley

     Dr James E Crowe

223. 
     Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire

     Article • Immunology, August 2012, Wiley

     Dr James E Crowe

224. 
     Influenza Virus Resistance to Human Neutralizing Antibodies

     Article • mBio, July 2012, ASM Journals

     Dr James E Crowe

225. 
     Respiratory Syncytial Virus Assembles into Structured Filamentous Virion Particles Independently of Host Cytoskeleton and Related Proteins

     Article • PLOS One, July 2012, PLOS

     Dr James E Crowe

226. 
     Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity

     Article • Genes and Immunity, June 2012, Nature

     Dr James E Crowe

227. 
     High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals

     Article • Genes and Immunity, May 2012, Nature

     Dr James E Crowe

228. 
     Human Respiratory Syncytial Virus Nucleoprotein and Inclusion Bodies Antagonize the Innate Immune Response Mediated by MDA5 and MAVS

     Article • Journal of Virology, May 2012, ASM Journals

     Dr James E Crowe

229. 
     Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes

     Article • PLOS One, May 2012, PLOS

     Dr James E Crowe

230. 
     Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

     Article • Proceedings of the National Academy of Sciences, April 2012, Proceedings of the National Academy of Sciences

     Dr James E Crowe

231. 
     Human Monoclonal Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses

     Article • Journal of Virology, March 2012, ASM Journals

     Dr James E Crowe, Dr Randy A Albrecht

232. 
     Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site

     Article • Nature Structural & Molecular Biology, March 2012, Springer Science + Business Media

     John Williams, Dr James E Crowe

233. 
     A Critical Phenylalanine Residue in the Respiratory Syncytial Virus Fusion Protein Cytoplasmic Tail Mediates Assembly of Internal Viral Proteins into Viral Filaments and Particles

     Article • mBio, February 2012, ASM Journals

     Dr James E Crowe

234. 
     Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity

     Article • Blood, January 2012, American Society of Hematology

     Dr James E Crowe, Daniel Moore

235. 
     Independent Structural Domains in Paramyxovirus Polymerase Protein

     Article • Journal of Biological Chemistry, January 2012, American Society for Biochemistry & Molecular Biology (ASBMB)

     Dr James E Crowe

236. 
     Viral Pneumonia

     Article • January 2012, Elsevier

     Dr James E Crowe

237. 
     Human Metapneumovirus

     Article • January 2012, Elsevier

     Dr James E Crowe

238. 
     Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection

     Article • Journal of Virology, December 2011, ASM Journals

     Dr James E Crowe

239. 
     Identification of potential human respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction and MHC binding assays

     Article • Journal of Immunological Methods, November 2011, Elsevier

     Dr James E Crowe

240. 
     Machine learning competition in immunology – Prediction of HLA class I binding peptides

     Article • Journal of Immunological Methods, November 2011, Elsevier

     Dr James E Crowe, Prof Gajendra PS Raghava

241. 
     Maturation-Induced Cloaking of Neutralization Epitopes on HIV-1 Particles

     Article • PLoS Pathogens, September 2011, PLOS

     Dr James E Crowe

242. 
     Epitope-Specific Human Influenza Antibody Repertoires Diversify by B Cell Intraclonal Sequence Divergence and Interclonal Convergence

     Article • The Journal of Immunology, August 2011, The American Association of Immunologists

     Dr James E Crowe

243. 
     A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin

     Article • Journal of Virology, August 2011, ASM Journals

     Dr James E Crowe

244. 
     Tribute to David T. Karzon, MD and Robert M. Chanock, MD

     Article • Vaccine, May 2011, Elsevier

     Dr James E Crowe

245. 
     Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication

     Article • Virology, April 2011, Elsevier

     Dr James E Crowe

246. 
     An Insertion Mutation That Distorts Antibody Binding Site Architecture Enhances Function of a Human Antibody

     Article • mBio, February 2011, ASM Journals

     Dr James E Crowe

247. 
     Human Metapneumovirus

     Article • January 2011, Elsevier

     Dr James E Crowe

248. 
     Respiratory Syncytial Virus

     Article • January 2011, Elsevier

     Dr James E Crowe

249. 
     Prevention of Fetal and Early Life Infections Through Maternal–Neonatal Immunization

     Article • January 2011, Elsevier

     Dr James E Crowe

250. 
     Respiratory Syncytial Virus and Human Metapneumovirus

     Article • January 2011, ASM Journals

     Dr James E Crowe

251. 
     Research Highlights: Highlights from the Latest Articles in Nanomedicine

     Article • Nanomedicine, December 2010, Taylor & Francis

     Dr James E Crowe

252. 
     Reply to Schlapbach et al

     Article • The Journal of Infectious Diseases, December 2010, Oxford University Press (OUP)

     Dr James E Crowe

253. 
     Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes

     Article • Nature Medicine, December 2010, Nature

     Dr James E Crowe

254. 
     Specificity for Human Hemoglobin Enhances Staphylococcus aureus Infection

     Article • Cell Host & Microbe, December 2010, Elsevier

     Dr Eric P Skaar, Dr James E Crowe

255. 
     Faculty of 1000 evaluation for A size threshold limits prion transmission and establishes phenotypic diversity.

     Article • October 2010, Faculty of 1000, Ltd.

     Dr James E Crowe

256. 
     Transforming Growth Factor Beta Is a Major Regulator of Human Neonatal Immune Responses following Respiratory Syncytial Virus Infection

     Article • Journal of Virology, October 2010, ASM Journals

     Dr James E Crowe

257. 
     Respiratory Syncytial Virus Induces Host RNA Stress Granules To Facilitate Viral Replication

     Article • Journal of Virology, September 2010, ASM Journals

     Dr James E Crowe

258. 
     Surfing a genetic association interaction network to identify modulators of antibody response to smallpox vaccine

     Article • Genes and Immunity, July 2010, Nature

     Dr James E Crowe

259. 
     Pseudovirion Particles Bearing Native HIV Envelope Trimers Facilitate a Novel Method for Generating Human Neutralizing Monoclonal Antibodies Against HIV

     Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, July 2010, Wolters Kluwer Health

     Dr James E Crowe

260. 
     Population‐Based Incidence of Human Metapneumovirus Infection among Hospitalized Children

     Article • The Journal of Infectious Diseases, June 2010, Oxford University Press (OUP)

     John Williams, Dr James E Crowe

261. 
     Regulatory T cell expression of CLA or α4β7 and skin or gut acute GVHD outcomes

     Article • Bone Marrow Transplantation, May 2010, Nature

     Dr James E Crowe

262. 
     Emerging studies of human HIV-specific antibody repertoires

     Article • Vaccine, May 2010, Elsevier

     Dr James E Crowe

263. 
     Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus

     Article • Science, March 2010, American Association for the Advancement of Science

     Dr James E Crowe

264. 
     Naturally Occurring Human Monoclonal Antibodies Neutralize both 1918 and 2009 Pandemic Influenza A (H1N1) Viruses

     Article • Journal of Virology, December 2009, ASM Journals

     Dr James E Crowe

265. 
     Faculty of 1000 evaluation for Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.

     Article • December 2009, Faculty of 1000, Ltd.

     Dr James E Crowe

266. 
     Faculty of 1000 evaluation for Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus.

     Article • December 2009, Faculty of 1000, Ltd.

     Dr James E Crowe

267. 
     Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches

     Article • Vaccine, December 2009, Elsevier

     Dr James E Crowe

268. 
     The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations

     Article • Molecular Immunology, December 2009, Elsevier

     Dr James E Crowe

269. 
     Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years

     Article • Virology Journal, September 2009, Springer Science + Business Media

     John Williams, Dr James E Crowe

270. 
     Faculty of 1000 evaluation for Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

     Article • September 2009, Faculty of 1000, Ltd.

     Dr James E Crowe

271. 
     The Pediatric Burden of Human Coronaviruses Evaluated for Twenty Years

     Article • The Pediatric Infectious Disease Journal, August 2009, Wolters Kluwer Health

     Dr James E Crowe

272. 
     Coronavirus infection and hospitalizations for acute respiratory illness in young children

     Article • Journal of Medical Virology, May 2009, Wiley

     Dr James E Crowe

273. 
     Single molecule–sensitive probes for imaging RNA in live cells

     Article • Nature Chemical Biology, April 2009, Springer Science + Business Media

     Dr James E Crowe

274. 
     Amphiregulin-Deficient Mice Develop Spasmolytic Polypeptide Expressing Metaplasia and Intestinal Metaplasia

     Article • Gastroenterology, April 2009, Elsevier

     Dr James E Crowe

275. 
     Capturing the Spectrum of Interaction Effects in Genetic Association Studies by Simulated Evaporative Cooling Network Analysis

     Article • PLoS Genetics, March 2009, PLOS

     Dr James E Crowe

276. 
     Faculty of 1000 evaluation for Antibody recognition of a highly conserved influenza virus epitope.

     Article • March 2009, Faculty of 1000, Ltd.

     Dr James E Crowe

277. 
     Faculty of 1000 evaluation for Antigen-specific human polyclonal antibodies from hyperimmunized cattle.

     Article • February 2009, Faculty of 1000, Ltd.

     Dr James E Crowe

278. 
     Faculty of 1000 evaluation for Estrogen directly activates AID transcription and function.

     Article • February 2009, Faculty of 1000, Ltd.

     Dr James E Crowe

279. 
     A Chimeric A2 Strain of Respiratory Syncytial Virus (RSV) with the Fusion Protein of RSV Strain Line 19 Exhibits Enhanced Viral Load, Mucus, and Airway Dysfunction

     Article • Journal of Virology, February 2009, ASM Journals

     Dr James E Crowe

280. 
     Faculty of 1000 evaluation for Engineering microRNA responsiveness to decrease virus pathogenicity.

     Article • November 2008, Faculty of 1000, Ltd.

     Dr James E Crowe

281. 
     Human metapneumovirus nucleoprotein and phosphoprotein interact and provide the minimal requirements for inclusion body formation

     Article • Journal of General Virology, October 2008, Society for General Microbiology

     Dr James E Crowe

282. 
     Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination

     Article • Genes and Immunity, October 2008, Nature

     Dr James E Crowe

283. 
     An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats

     Article • Journal of Virology, September 2008, ASM Journals

     Dr James E Crowe

284. 
     Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope

     Article • Vaccine, September 2008, Elsevier

     Dr James E Crowe

285. 
     Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors

     Article • Nature, August 2008, Springer Science + Business Media

     Dr James E Crowe

286. 
     Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2

     Article • Proceedings of the National Academy of Sciences, July 2008, Proceedings of the National Academy of Sciences

     Dr James E Crowe

287. 
     Genetic Basis for Adverse Events after Smallpox Vaccination

     Article • The Journal of Infectious Diseases, July 2008, Oxford University Press (OUP)

     Dr James E Crowe

288. 
     An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies

     Article • Journal of Immunological Methods, July 2008, Elsevier

     Dr James E Crowe

289. 
     Functional Maturation of the Human Antibody Response to Rotavirus

     Article • The Journal of Immunology, March 2008, The American Association of Immunologists

     Dr Bidadi V Prasad, Dr James E Crowe

290. 
     Immunodominance of the VH1-46 Antibody Gene Segment in the Primary Repertoire of Human Rotavirus-Specific B Cells Is Reduced in the Memory Compartment through Somatic Mutation of Nondominant Clones

     Article • The Journal of Immunology, February 2008, The American Association of Immunologists

     Dr James E Crowe

291. 
     A Clinical Isolate Strain of Respiratory Syncytial Virus (RSV) Causes Airway Obstruction and Histopathology in Mice Similar to Severe RSV Disease in Infants

     Article • Journal of Allergy and Clinical Immunology, February 2008, Elsevier

     Dr James E Crowe

292. 
     Human Metapneumovirus

     Article • January 2008, Elsevier

     John Williams, Dr James E Crowe

293. 
     Respiratory Syncytial Virus

     Article • January 2008, Elsevier

     Dr James E Crowe

294. 
     Faculty of 1000 evaluation for Duration of humoral immunity to common viral and vaccine antigens.

     Article • November 2007, Faculty of 1000, Ltd.

     Dr James E Crowe

295. 
     Faculty of 1000 evaluation for Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.

     Article • October 2007, Faculty of 1000, Ltd.

     Dr James E Crowe

296. 
     Faculty of 1000 evaluation for A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis.

     Article • October 2007, Faculty of 1000, Ltd.

     Dr James E Crowe

297. 
     Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats

     Article • Journal of Virology, October 2007, ASM Journals

     Dr James E Crowe

298. 
     Genetic Predisposition for Adverse Events after Vaccination

     Article • The Journal of Infectious Diseases, July 2007, Oxford University Press (OUP)

     Dr James E Crowe

299. 
     Evaporative cooling feature selection for genotypic data involving interactions

     Article • Bioinformatics, June 2007, Oxford University Press (OUP)

     Dr James E Crowe

300. 
     A Recombinant Human Monoclonal Antibody to Human Metapneumovirus Fusion Protein That Neutralizes Virus In Vitro and Is Effective Therapeutically In Vivo

     Article • Journal of Virology, May 2007, ASM Journals

     Dr James E Crowe

301. 
     Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naïve and memory B cells

     Article • Molecular Immunology, March 2007, Elsevier

     Dr James E Crowe

302. 
     Faculty of 1000 evaluation for Ab and T cell epitopes of influenza A virus, knowledge and opportunities.

     Article • February 2007, Faculty of 1000, Ltd.

     Dr James E Crowe

303. 
     Using the natural evolution of a rotavirus-specific human monoclonal antibody to predict the complex topography of a viral antigenic site

     Article • Immunome Research, January 2007, Springer Science + Business Media

     Dr James E Crowe

304. 
     Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools

     Article • Journal of Molecular Recognition, January 2007, Wiley

     Dr James E Crowe, Prof Gajendra PS Raghava, Dr. Erwin L J Roggen

305. 
     Tissue-Specific Regulation of CD8+ T-Lymphocyte Immunodominance in Respiratory Syncytial Virus Infection

     Article • Journal of Virology, December 2006, ASM Journals

     Dr James E Crowe

306. 
     Faculty of 1000 evaluation for The histopathology of fatal untreated human respiratory syncytial virus infection.

     Article • December 2006, Faculty of 1000, Ltd.

     Dr James E Crowe

307. 
     Faculty of 1000 evaluation for Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

     Article • December 2006, Faculty of 1000, Ltd.

     Dr James E Crowe

308. 
     Nanoscale tools for rapid and sensitive diagnosis of viruses

     Article • Future Virology, November 2006, Future Medicine

     Dr James E Crowe

309. 
     Faculty of 1000 evaluation for Low-coverage vaccination strategies for the conservation of endangered species.

     Article • October 2006, Faculty of 1000, Ltd.

     Dr James E Crowe

310. 
     Human Metapneumovirus Fusion Protein Vaccines That Are Immunogenic and Protective in Cotton Rats

     Article • Journal of Virology, October 2006, ASM Journals

     Dr James E Crowe

311. 
     Examination of a Fusogenic Hexameric Core from Human Metapneumovirus and Identification of a Potent Synthetic Peptide Inhibitor from the Heptad Repeat 1 Region

     Article • Journal of Virology, October 2006, ASM Journals

     Dr James E Crowe

312. 
     Introduction

     Article • Seminars in Pediatric Infectious Diseases, October 2006, Elsevier

     Dr James E Crowe

313. 
     Low expression of the interleukin (IL)-4 receptor alpha chain and reduced signalling via the IL-4 receptor complex in human neonatal B cells

     Article • Immunology, September 2006, Wiley

     Dr James E Crowe

314. 
     Feature Selection using a Random Forests Classifier for the Integrated Analysis of Multiple Data Types

     Article • September 2006, Institute of Electrical & Electronics Engineers (IEEE)

     Dr James E Crowe

315. 
     Cellular Immune Responses to Diluted and Undiluted Aventis Pasteur Smallpox Vaccine

     Article • The Journal of Infectious Diseases, August 2006, Oxford University Press (OUP)

     Dr James E Crowe, Dr Thomas R Talbot

316. 
     Cytokine Expression Patterns Associated with Systemic Adverse Events following Smallpox Immunization

     Article • The Journal of Infectious Diseases, August 2006, Oxford University Press (OUP)

     Dr James E Crowe

317. 
     Faculty of 1000 evaluation for A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines.

     Article • July 2006, Faculty of 1000, Ltd.

     Dr James E Crowe

318. 
     Faculty of 1000 evaluation for Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.

     Article • July 2006, Faculty of 1000, Ltd.

     Dr James E Crowe

319. 
     :Vaccines: Frontiers in Design and Development

     Article • Clinical Infectious Diseases, July 2006, Oxford University Press (OUP)

     Dr James E Crowe

320. 
     Automated image analysis of atomic force microscopy images of rotavirus particles

     Article • Ultramicroscopy, June 2006, Elsevier

     Dr James E Crowe

321. 
     Hybrid grammar-based approach to nonlinear dynamical system identification from biological time series

     Article • Physical Review E, February 2006, American Physical Society (APS)

     Dr James E Crowe

322. 
     Detection of viral infections using colloidal quantum dots

     Article • February 2006, SPIE

     Dr James E Crowe

323. 
     The Role of Human Metapneumovirus in Upper Respiratory Tract Infections in Children: A 20‐Year Experience

     Article • The Journal of Infectious Diseases, February 2006, Oxford University Press (OUP)

     John Williams, Dr James E Crowe

324. 
     The Transmembrane Domain of the Respiratory Syncytial Virus F Protein Is an Orientation-Independent Apical Plasma Membrane Sorting Sequence

     Article • Journal of Virology, February 2006, ASM Journals

     Dr James E Crowe

325. 
     Viral Pneumonia

     Article • January 2006, Elsevier

     Dr James E Crowe

326. 
     Rotavirus-Specific CD5+ B Cells in Young Children Exhibit a Distinct Antibody Repertoire Compared with CD5− B Cells

     Article • Human Immunology, January 2006, Elsevier

     Dr James E Crowe

327. 
     Reply

     Article • Journal of Allergy and Clinical Immunology, January 2006, Elsevier

     Dr James E Crowe

328. 
     Transcriptional Control of Activation-Induced Cytidine Deaminase and Error-Prone DNA Polymerases Is Functionally Mature in the B Cells of Infants at Birth

     Article • Human Immunology, January 2006, Elsevier

     Dr James E Crowe

329. 
     Faculty of 1000 evaluation for Altered TCR signaling from geometrically repatterned immunological synapses.

     Article • November 2005, Faculty of 1000, Ltd.

     Dr James E Crowe

330. 
     Human Metapneumovirus Infection Plays an Etiologic Role in Acute Asthma Exacerbations Requiring Hospitalization in Adults

     Article • The Journal of Infectious Diseases, October 2005, Oxford University Press (OUP)

     John Williams, Dr James E Crowe

331. 
     The Transmembrane Domain of the Respiratory Syncytial Virus F Protein Is an Orientation-Independent Apical Plasma Membrane Sorting Sequence

     Article • Journal of Virology, October 2005, ASM Journals

     Dr James E Crowe

332. 
     Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses in Adult Recipients of Hematopoietic Stem Cell Transplants for Hematologic Malignancies

     Article • Biology of Blood and Marrow Transplantation, October 2005, Elsevier

     Dr James E Crowe

333. 
     A Prospective Study Comparing Human Metapneumovirus with Other Respiratory Viruses in Adults with Hematologic Malignancies and Respiratory Tract Infections

     Article • The Journal of Infectious Diseases, September 2005, Oxford University Press (OUP)

     John Williams, Dr James E Crowe

334. 
     The Cotton Rat (Sigmodon hispidus) Is a Permissive Small Animal Model of Human Metapneumovirus Infection, Pathogenesis, and Protective Immunity

     Article • Journal of Virology, September 2005, ASM Journals

     Dr James E Crowe

335. 
     Identification of an H-2Db-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus

     Article • Virology, July 2005, Elsevier

     Dr James E Crowe

336. 
     Faculty of 1000 evaluation for Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

     Article • June 2005, Faculty of 1000, Ltd.

     Dr James E Crowe

337. 
     Human metapneumovirus infection in children hospitalized for wheezing

     Article • Journal of Allergy and Clinical Immunology, June 2005, Elsevier

     John Williams, Dr James E Crowe

338. 
     Natural Evolution of a Human Virus-Specific Antibody Gene Repertoire by Somatic Hypermutation Requires Both Hotspot-Directed and Randomly-Directed Processes

     Article • Human Immunology, June 2005, Elsevier

     Dr James E Crowe

339. 
     Faculty of 1000 evaluation for Stable antibody expression at therapeutic levels using the 2A peptide.

     Article • May 2005, Faculty of 1000, Ltd.

     Dr James E Crowe

340. 
     Faculty of 1000 evaluation for Serum IgG mediates mucosal immunity against rotavirus infection.

     Article • May 2005, Faculty of 1000, Ltd.

     Dr James E Crowe

341. 
     Pseudovirion Particle Production by Live Poxvirus Human Immunodeficiency Virus Vaccine Vector Enhances Humoral and Cellular Immune Responses

     Article • Journal of Virology, May 2005, ASM Journals

     Dr James E Crowe

342. 
     Prevalence of Reovirus‐Specific Antibodies in Young Children in Nashville, Tennessee

     Article • The Journal of Infectious Diseases, April 2005, Oxford University Press (OUP)

     Dr James E Crowe

343. 
     Application of semiconductor fluorescent nanocrystals as optical probes for rapid early viral detection

     Article • April 2005, SPIE

     Dr James E Crowe

344. 
     Progression of Respiratory Syncytial Virus Infection Monitored by Fluorescent Quantum Dot Probes

     Article • Nano Letters, April 2005, American Chemical Society (ACS)

     Dr James E Crowe

345. 
     Differential Regulation of Granzyme and Perforin in Effector and Memory T Cells following Smallpox Immunization

     Article • The Journal of Immunology, March 2005, The American Association of Immunologists

     Dr Thomas R Talbot, Dr James E Crowe

346. 
     VH1-46 Is the Dominant Immunoglobulin Heavy Chain Gene Segment in Rotavirus-Specific Memory B Cells Expressing the Intestinal Homing Receptor  4 7

     Article • The Journal of Immunology, March 2005, The American Association of Immunologists

     Dr James E Crowe

347. 
     Smallpox Vaccination Does Not Elevate Systemic Levels of Prothrombotic Proteins Associated with Ischemic Cardiac Events

     Article • The Journal of Infectious Diseases, March 2005, Oxford University Press (OUP)

     Dr James E Crowe, Dr Thomas R Talbot

348. 
     Faculty of 1000 evaluation for Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?

     Article • February 2005, Faculty of 1000, Ltd.

     Dr James E Crowe

349. 
     Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus

     Article • Virology, January 2005, Elsevier

     Dr James E Crowe

350. 
     Introduction

     Article • The Pediatric Infectious Disease Journal, November 2004, Wolters Kluwer Health

     Dr James E Crowe

351. 
     Human Metapneumovirus as a Major Cause of Human Respiratory Tract Disease

     Article • The Pediatric Infectious Disease Journal, November 2004, Wolters Kluwer Health

     Dr James E Crowe

352. 
     Vaccination Success Rate and Reaction Profile With Diluted and Undiluted Smallpox Vaccine

     Article • JAMA, September 2004, American Medical Association (AMA)

     Dr James E Crowe, Dr Thomas R Talbot

353. 
     Faculty of 1000 evaluation for A role for Streptococcus pneumoniae in virus-associated pneumonia.

     Article • July 2004, Faculty of 1000, Ltd.

     Dr James E Crowe

354. 
     Faculty of 1000 evaluation for An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

     Article • July 2004, Faculty of 1000, Ltd.

     Dr James E Crowe

355. 
     Human Metapneumovirus and Lower Respiratory Tract Disease in Children

     Article • New England Journal of Medicine, April 2004, New England Journal of Medicine (NEJM/MMS)

     Dr James E Crowe

356. 
     Adverse Events after Smallpox Immunizations Are Associated with Alterations in Systemic Cytokine Levels

     Article • The Journal of Infectious Diseases, April 2004, Oxford University Press (OUP)

     Dr James E Crowe, Dr Thomas R Talbot

357. 
     Effect of Zinc Salts on Respiratory Syncytial Virus Replication

     Article • Antimicrobial Agents and Chemotherapy, March 2004, ASM Journals

     Dr James E Crowe

358. 
     Faculty of 1000 evaluation for Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.

     Article • February 2004, Faculty of 1000, Ltd.

     Dr James E Crowe

359. 
     Human Metapneumovirus and Lower Respiratory Tract Disease in Otherwise Healthy Infants and Children

     Article • New England Journal of Medicine, January 2004, New England Journal of Medicine (NEJM/MMS)

     John Williams, Dr James E Crowe

360. 
     B-Cell Development

     Article • January 2004, Elsevier

     Dr James E Crowe

361. 
     Apical recycling systems regulate directional budding of respiratory syncytial virus from polarized epithelial cells

     Article • Proceedings of the National Academy of Sciences, November 2003, Proceedings of the National Academy of Sciences

     Dr James E Crowe

362. 
     Fatal Hemophagocytic Lymphohistiocytosis Associated with Epstein-Barr Virus Infection in a Patient with a Novel Mutation in the Signaling Lymphocytic Activation Molecule--Associated Protein

     Article • Clinical Infectious Diseases, November 2003, Oxford University Press (OUP)

     Dr James E Crowe

363. 
     Infant and Adult Human B Cell Responses to Rotavirus Share Common Immunodominant Variable Gene Repertoires

     Article • The Journal of Immunology, October 2003, The American Association of Immunologists

     Dr James E Crowe

364. 
     Faculty of 1000 evaluation for Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

     Article • July 2003, Faculty of 1000, Ltd.

     Dr James E Crowe

365. 
     Respiratory Syncytial Virus Nucleoprotein-Specific Cytotoxic T-Cell Epitopes in a South African Population of Diverse HLA Types Are Conserved in Circulating Field Strains

     Article • Journal of Virology, July 2003, ASM Journals

     Dr James E Crowe

366. 
     Immunology of viral respiratory tract infection in infancy

     Article • Paediatric Respiratory Reviews, June 2003, Elsevier

     Dr James E Crowe

367. 
     CD154 Regulates Primate Humoral Immunity to Influenza

     Article • American Journal of Transplantation, June 2003, Wiley

     Dr James E Crowe

368. 
     Planar growth faults in double-layered or triple-layered (Ca,Sr)-ruthenate single crystals by the self-flux technique

     Article • Journal of Crystal Growth, May 2003, Elsevier

     Dr James E Crowe

369. 
     Faculty of 1000 evaluation for Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections.

     Article • April 2003, Faculty of 1000, Ltd.

     Dr James E Crowe

370. 
     Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein

     Article • Immunology, April 2003, Wiley

     Dr James E Crowe

371. 
     Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles

     Article • Journal of Immunological Methods, April 2003, Elsevier

     Dr James E Crowe

372. 
     Faculty of 1000 evaluation for Mortality associated with influenza and respiratory syncytial virus in the United States.

     Article • January 2003, Faculty of 1000, Ltd.

     Dr James E Crowe

373. 
     Faculty of 1000 evaluation for Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways.

     Article • November 2002, Faculty of 1000, Ltd.

     Dr James E Crowe

374. 
     Faculty of 1000 evaluation for A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children.

     Article • November 2002, Faculty of 1000, Ltd.

     Dr James E Crowe

375. 
     Faculty of 1000 evaluation for Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.

     Article • November 2002, Faculty of 1000, Ltd.

     Dr James E Crowe

376. 
     The Human Polymeric Immunoglobulin Receptor Facilitates Invasion of Epithelial Cells by Streptococcus pneumoniae in a Strain-Specific and Cell Type-Specific Manner

     Article • Infection and Immunity, September 2002, ASM Journals

     Dr James E Crowe

377. 
     PNEUMOCYSTIS CARINII PNEUMONIA IN A GIRL WITH A MIDBRAIN GLIOMA

     Article • Pediatric Hematology and Oncology, January 2002, Taylor & Francis

     Dr James E Crowe

378. 
     Influence of Maternal Antibodies on Neonatal Immunization against Respiratory Viruses

     Article • Clinical Infectious Diseases, November 2001, Oxford University Press (OUP)

     Dr James E Crowe

379. 
     Respiratory syncytial virus vaccine development

     Article • Vaccine, October 2001, Elsevier

     Dr James E Crowe

380. 
     Passively Acquired Antibodies Suppress Humoral But Not Cell-Mediated Immunity in Mice Immunized with Live Attenuated Respiratory Syncytial Virus Vaccines

     Article • The Journal of Immunology, October 2001, The American Association of Immunologists

     Dr James E Crowe

381. 
     CD40-Ligand in Primate Cardiac Allograft and Viral Immunity

     Article • Immunologic Research, January 2001, Springer Science + Business Media

     Dr James E Crowe

382. 
     Genetic and Structural Determinants of Virus Neutralizing Antibodies

     Article • Immunologic Research, January 2001, Springer Science + Business Media

     Dr James E Crowe

383. 
     Recurrent Achromobacter xylosoxidans Bacteremia Associated with Persistent Lymph Node Infection in a Patient with Hyper-Immunoglobulin M Syndrome

     Article • Clinical Infectious Diseases, November 2000, Oxford University Press (OUP)

     Dr James E Crowe

384. 
     Recurrent Pneumococcal Arthritis as the Presenting Manifestation of X-Linked Agammaglobulinemia

     Article • Clinical Infectious Diseases, November 2000, Oxford University Press (OUP)

     Dr James E Crowe

385. 
     Aktuelle Ansätze zur Impfstoffentwicklung gegen Respiratory-Syncytial-Virus (RSV)

     Article • Monatsschrift Kinderheilkunde, November 2000, Springer Science + Business Media

     Dr James E Crowe

386. 
     Evaluation of a Live, Cold‐Passaged, Temperature‐Sensitive, Respiratory Syncytial Virus Vaccine Candidate in Infancy

     Article • The Journal of Infectious Diseases, November 2000, Oxford University Press (OUP)

     Dr James E Crowe

387. 
     A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3

     Article • Nature Medicine, January 2000, Nature

     Dr James E Crowe

388. 
     Passive IgA Monoclonal Antibody Is No More Effective Than IgG at Protecting Mice from Mucosal Challenge with Respiratory Syncytial Virus

     Article • The Journal of Infectious Diseases, October 1999, Oxford University Press (OUP)

     Dr James E Crowe, Dr Yi-Wei Tang

389. 
     The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo

     Article • Virus Research, January 1999, Elsevier

     Dr James E Crowe

390. 
     Monoclonal Antibody-Resistant Mutants Selected with a Respiratory Syncytial Virus-Neutralizing Human Antibody Fab Fragment (Fab 19) Define a Unique Epitope on the Fusion (F) Glycoprotein

     Article • Virology, December 1998, Elsevier

     Dr James E Crowe

391. 
     Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines

     Article • Vaccine, August 1998, Elsevier

     Dr James E Crowe

392. 
     Isolation of a Second Recombinant Human Respiratory Syncytial Virus Monoclonal Antibody Fragment (Fab RSVF2–5) that Exhibits Therapeutic Efficacy In Vivo

     Article • The Journal of Infectious Diseases, April 1998, Oxford University Press (OUP)

     Dr James E Crowe

393. 
     Evaluation of a Live, Attenuated Respiratory Syncytial Virus (RSV)Vaccine Candidate, cpts 248/404, in Infancy • 931

     Article • Pediatric Research, April 1998, Springer Science + Business Media

     Dr James E Crowe

394. 
     Evaluation of Two Live, Cold‐Passaged, Temperature‐Sensitive Respiratory Syncytial Virus Vaccines in Chimpanzees and in Human Adults, Infants, and Children

     Article • The Journal of Infectious Diseases, December 1997, Oxford University Press (OUP)

     Dr James E Crowe

395. 
     Nucleotide Sequence Analysis of the Respiratory Syncytial Virus Subgroup A Cold-Passaged (cp) Temperature Sensitive (ts)cpts-248/404 Live Attenuated Virus Vaccine Candidate

     Article • Virology, November 1996, Elsevier

     Dr James E Crowe

396. 
     The role of antibodies in respiratory viral immunity

     Article • Seminars in Virology, August 1996, Elsevier

     Dr James E Crowe

397. 
     Live Subgroup B Respiratory Syncytial Virus Vaccines that Are Attenuated, Genetically Stable, and Immunogenic in Rodents and Nonhuman Primates

     Article • The Journal of Infectious Diseases, April 1996, Oxford University Press (OUP)

     Dr James E Crowe

398. 
     Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene

     Article • Virus Genes, January 1996, Springer Science + Business Media

     Dr James E Crowe

399. 
     Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization

     Article • Vaccine, June 1995, Elsevier

     Dr James E Crowe

400. 
     A Cold-Passaged, Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes

     Article • Virology, April 1995, Elsevier

     Dr James E Crowe

401. 
     Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus

     Article • Vaccine, January 1995, Elsevier

     Dr James E Crowe

402. 
     Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV) A meeting report of the WHO Programme for Vaccine Development

     Article • Vaccine, January 1995, Elsevier

     Dr James E Crowe

403. 
     An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

     Article • Virus Research, April 1994, Elsevier

     Dr James E Crowe

404. 
     Recombinant human respiratory syncytial virus (RSV)monoclonal antibody Fab is effective therapeutically when introduced directlyinto the lungs of RSV-infected mice.

     Article • Proceedings of the National Academy of Sciences, February 1994, Proceedings of the National Academy of Sciences

     Dr James E Crowe

405. 
     A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees

     Article • Vaccine, January 1994, Elsevier

     Dr James E Crowe

406. 
     Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis

     Article • Vaccine, January 1994, Elsevier

     Dr James E Crowe

407. 
     A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV

     Article • Vaccine, January 1993, Elsevier

     Dr James E Crowe

408. 
     Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

     Article • Proceedings of the National Academy of Sciences, November 1992, Proceedings of the National Academy of Sciences

     Dr James E Crowe